(+)-Lariciresinol 4,4’-O-bis-β-D-glucopyranoside
(+)-Lariciresinol 4,4'-O-bis-β-D-glucopyranoside is a COX-2 inhibitor. (+)-Lariciresinol 4,4'-O-bis-β-D-glucopyranoside exhibits inhibitory effects on LPS (HY-D1056)-induced COX-2 activity in mouse peritoneal macrophages and reduces PGE2 levels in the supernatant. (+)-Lariciresinol 4,4'-O-bis-β-D-glucopyranoside can be used for inflammation-related research.
For research use only. We do not sell to patients.
- CAS No.: 936331-98-5
- Formula: C32H44O16
- Molecular Weight:684.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
COX-2 |
In Vitro
(+)-Lariciresinol 4,4’-O-bis-β-D-glucopyranoside (Compound 7) (10 μM; 1 h) inhibits COX-2 activity in murine peritoneal macrophages, exhibiting an inhibition rate of 60.3%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 936331-98-5
-
Molecular Weight 684.68
-
Formula C32H44O16
-
SMILES
OC[C@H]1[C@H](C2=CC(OC)=C(C=C2)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)OC[C@H]1CC4=CC(OC)=C(C=C4)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(+)-Lariciresinol 4,4’-O-bis-β-D-glucopyranoside Related Classifications
HY-N21854 Related Classifications
Powered by Bioz